This month’s investment candidate is a New Jersey-based biopharmaceutical company, Insmed (INSM). Insmed has developed a unique inhaled drug delivery technology that enables potential treatments for lung infections and lung diseases including cystic fibrosis. I think the stock has the potential to double in two years. Also note in today’s issue that Guidance Software (GUID) is now rated Sell. The company reported first quarter revenue and earnings that missed analyst expectations, blaming a challenging sales environment and the government’s sequestration. I’ve lost confidence in company management at this point and recommend that you sell GUID.
